English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background   MET  is a proto-oncogene with its copy number (CN) alterations been reported in some cancers, but not in primary intestinal diffuse large B-cell lymphoma (PI-DLBL) yet.    Methods  In this retrospective study, we performed histology and chart reviews, immunohistochemistry and quantitative polymerase chain reaction for  MET  CN alterations on 28 surgically resected PI-DLBLs.    Results  There were 12 men and 16 women with a median age of 70 and a mean follow-up of 32 months. The median  MET  CN was 2.20 (range, 1.04 to 3.35). CN gain was observed in 11 cases, including 5 with CN greater than 3. Nine patients (32%) had diploid CN and eight (29%) with CN loss. Patients with gain or diploid CN showed significantly worse prognosis ( P  = 0.046) than those with CN loss. Furthermore,  MET  CN greater than 3 was associated with an adverse outcome ( P  = 0.003). Intestinal perforation at presentation was the sole clinicopathological factor associated with a poor prognosis ( P  = 0.004) and perforation was correlated with CN greater than 3 ( P  = 0.002).    Conclusions  Our finding of  MET  CN gain as a poor prognostic factor in PI-DLBL patients might serve as the rationale for targeting  MET  signaling pathway in the treatment of these patients.

High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma